1. Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease.

    Journal of Biological Chemistry 289(39):27080 (2014) PMID 25118284 PMCID PMC4175345

    Passive immunization with anti-amyloid-β peptide (Aβ) antibodies is effective in animal models of Alzheimer disease. With the advent of efficient in vitro selection technologies, the novel class of designed ankyrin repeat proteins (DARPins) presents an attractive alternative to the immunoglobuli...
  2. Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease.

    Journal of Biological Chemistry 289(39):27080 (2014) PMID 25118284 PMCID PMC4175345

    Passive immunization with anti-amyloid-β peptide (Aβ) antibodies is effective in animal models of Alzheimer disease. With the advent of efficient in vitro selection technologies, the novel class of designed ankyrin repeat proteins (DARPins) presents an attractive alternative to the immunoglobuli...
  3. ["Making the wishes of residents a priority"].

    Pflege Zeitschrift 66(3):160 (2013) PMID 23513586

  4. [Structured and institutionalized handling of ethics questions in inpatient geriatric long-term care: frustration, anger and guilt feelings].

    Pflege Zeitschrift 65(1):46 (2012) PMID 22338260

  5. The role of brain macrophages on the clearance of amyloid plaques following the treatment of Tc2576 with BIIB037

    Alzheimer's & Dementia 7(4):S700 (2011)

  6. Molecular characterization and preclinical efficacy

    Alzheimer's & Dementia 7(4):S457 (2011)

  7. [Extreme situations in nursing - peers support professionals: not abandoning nurses].

    Pflege Zeitschrift 63(11):660 (2010) PMID 21086670

  8. DARPins against the amyloid-beta petide selected via ribosome display

    Alzheimer's & Dementia 6(4):S539 (2010)

  9. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

    Journal of Neuroscience 28(25):6333 (2008) PMID 18562603 PMCID PMC3329761

    Complement factor C3 is the central component of the complement system and a key inflammatory protein activated in Alzheimer's disease (AD). Previous studies demonstrated that inhibition of C3 by overexpression of soluble complement receptor-related protein y in an AD mouse model led to reduced ...
  10. Novel Abeta immunogens: is shorter better?

    Current Alzheimer Research 4(4):427 (2007) PMID 17908047

    Active and passive Abeta immunotherapy in Alzheimer's disease (AD)-like mouse models lowers cerebral amyloid-beta protein (Abeta) levels, especially if given early in the disease process, and improves cognitive deficits. In 2002, a Phase IIa clinical trial was halted due to meningoencephalitis i...
  11. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.

    Neurobiology of Aging 28(6):813 (2007) PMID 16725229

    Immunization of humans and APP-tg mice with full-length beta-amyloid (Abeta) results in reduced cerebral Abeta levels. However, due to adverse events in the AN1792 trial, alternative vaccines are required. We investigated dendrimeric Abeta1-15 (dAbeta1-15), which is composed of 16 copies of Abet...
  12. Dendrimeric Aβ1–15 is an effective immunogen in wildtype and APP-tg mice

    Neurobiology of Aging 28(6):813 (2007)

    Immunization of humans and APP-tg mice with full-length β-amyloid (Aβ) results in reduced cerebral Aβ levels. However, due to adverse events in the AN1792 trial, alternative vaccines are required. We investigated dendrimeric Aβ1–15 (dAβ1–15), which is composed of 16 copies of Aβ1–15 peptide...
  13. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response.

    Journal of Neuroscience 26(18):4717 (2006) PMID 16672644

    Amyloid-beta (Abeta) immunotherapy lowers cerebral Abeta and improves cognition in mouse models of Alzheimer's disease (AD). A clinical trial using active immunization with Abeta1-42 was suspended after approximately 6% of patients developed meningoencephalitis, possibly because of a T-cell reac...
  14. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice.

    Glia 53(7):776 (2006) PMID 16534778

    Activated microglia and reactive astrocytes invade and surround cerebral beta amyloid (Abeta) plaques in Alzheimer's disease (AD), but the role of microglia in plaque development is still unclear. In this study, minocycline was administered for 3 months, prior to and early in Abeta plaque format...
  15. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.

    Rejuvenation Research 9(1):77 (2006) PMID 16608400

    Alzheimer disease (AD), the most common form of dementia, is without an effective cure or preventive treatment. Recently, amyloid-beta protein (Abeta) has become a major therapeutic target. Many efforts are underway to either reduce the production of Abeta or enhance its clearance. In 1999, Sche...
  16. P4-318:Short Aβ immunogens reduce cerebral Aβ load and learning deficits in an APPTG AD mouse model in the absence of an abeta-specific cellular immune response

    Alzheimer's & Dementia 2(3):S610 (2006)

  17. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G).

    Vaccine 23(44):5149 (2005) PMID 16054274

    Abeta vaccination or passive transfer of human-specific anti-Abeta antibodies are approaches under investigation to prevent and/or treat Alzheimer's disease (AD). Successful active Abeta vaccination requires a strong and safe adjuvant to induce anti-Abeta antibody formation. We compared the adju...
  18. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) andE. colienterotoxin LT(R192G)

    Vaccine 23(44):5149 (2005)

    Aβ vaccination or passive transfer of human-specific anti-Aβ antibodies are approaches under investigation to prevent and/or treat Alzheimer's disease (AD). Successful active Aβ vaccination requires a strong and safe adjuvant to induce anti-Aβ antibody formation. We compared the adjuvants m...
  19. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.

    Neurodegenerative Diseases 2(5):267 (2005) PMID 16909008

    Active amyloid beta (A beta) vaccination has been shown to be effective in clearing cerebral A beta and improving cognitive function in mouse models of Alzheimer's disease. However, an A beta vaccine clinical trial was suspended after meningoencephalitis was detected in a subset of subjects. Pas...
  20. P4-416 Novel formulations for an Alzheimer's disease vaccine

    Neurobiology of Aging 25:S592 (2004)